Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00108758 · ClinicalTrials.gov registry record · Phase 2
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
A Phase 2 study of Congenital Bleeding Disorder and Haemophilia A With Inhibitors, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 20
- Study locations
NCT00108758: Completed Phase 2 study of Congenital Bleeding Disorder and Haemophilia A With Inhibitors, sponsored by Novo Nordisk A/S.
NCT00108758 is a Phase 2 study of Congenital Bleeding Disorder and Haemophilia A With Inhibitors that has completed, run by Novo Nordisk A/S. The registered enrollment target is 23 participants, below the 136-participant average among 8 other Congenital Bleeding Disorder trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00108758, a Phase 2 study of Congenital Bleeding Disorder and Haemophilia A With Inhibitors, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is conducted in Africa, Asia, Europe, South America, and the United States of America (USA). The purpose of this study is to evaluate the effectiveness of secondary prophylactic treatment with NovoSeven® in haemophilia A and B patients with inhibitors.
Conditions Studied
Interventions
- DRUG activated recombinant human factor VII
Study Locations (20)
Other
- Novo Nordisk Investigational Site - Ciudad Autónoma de Bs. As.
- Novo Nordisk Investigational Site - Belo Horizonte
- Novo Nordisk Investigational Site - Recife
- Novo Nordisk Investigational Site - Ribeirão Preto
- Novo Nordisk Investigational Site - Sofia
California
- Novo Nordisk Investigational Site - Berkeley
- Novo Nordisk Investigational Site - Los Angeles
Pennsylvania
- Novo Nordisk Investigational Site - Philadelphia
- Novo Nordisk Investigational Site - Philadelphia
Illinois
- Novo Nordisk Investigational Site - Chicago
Indiana
- Novo Nordisk Investigational Site - Indianapolis
Iowa
- Novo Nordisk Investigational Site - Iowa City
Louisiana
- Novo Nordisk Investigational Site - New Orleans
Massachusetts
- Novo Nordisk Investigational Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2004-03 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
What the finished NCT00108758 record still lists
NCT00108758 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 136-participant average among 8 other Congenital Bleeding Disorder trials with a reported enrollment target (83% lower).
The record links to 3 conditions, with Congenital Bleeding Disorder appearing as the primary indexed condition, and to 1 intervention - of which activated recombinant human factor VII is the first listed.
NCT00108758 names 20 study sites across 14 states, led by Other, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00108758 about?
NCT00108758 is a clinical study titled "Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia". This trial is conducted in Africa, Asia, Europe, South America, and the United States of America (USA). The purpose of this study is to evaluate the effectiveness of secondary prophylactic treatment with NovoSeven® in haemophilia A and B patients with inhibitors.
What is the current status of trial NCT00108758?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2004-03. Estimated completion is 2005-11.
What conditions does trial NCT00108758 study?
This clinical trial studies the following conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors.
What interventions are being tested in trial NCT00108758?
The interventions under investigation include: activated recombinant human factor VII (DRUG).
Who is sponsoring clinical trial NCT00108758?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00108758 being conducted?
This trial has 20 study locations across California, Illinois, Indiana, Iowa, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Bleeding Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00108758's enrollment target sits among peer trials
23 9th of 8 the lowest of 8 other Congenital Bleeding Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Congenital Bleeding Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)
COMPLETED
-
Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A
COMPLETED · Phase 3
-
Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A
COMPLETED · Phase 3
-
Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B
COMPLETED · Phase 3
-
Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors
COMPLETED · Phase 3
-
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia